These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

801 related articles for article (PubMed ID: 11587223)

  • 1. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug.
    Gout PW; Buckley AR; Simms CR; Bruchovsky N
    Leukemia; 2001 Oct; 15(10):1633-40. PubMed ID: 11587223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro studies on the lymphoma growth-inhibitory activity of sulfasalazine.
    Gout PW; Simms CR; Robertson MC
    Anticancer Drugs; 2003 Jan; 14(1):21-9. PubMed ID: 12544255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The xc- cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine.
    Guan J; Lo M; Dockery P; Mahon S; Karp CM; Buckley AR; Lam S; Gout PW; Wang YZ
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):463-72. PubMed ID: 19104813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy.
    Doxsee DW; Gout PW; Kurita T; Lo M; Buckley AR; Wang Y; Xue H; Karp CM; Cutz JC; Cunha GR; Wang YZ
    Prostate; 2007 Feb; 67(2):162-71. PubMed ID: 17075799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB.
    Chung WJ; Sontheimer H
    J Neurochem; 2009 Jul; 110(1):182-93. PubMed ID: 19457125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenomic approach reveals a role for the x(c)- cystine/glutamate antiporter in growth and celastrol resistance of glioma cell lines.
    Pham AN; Blower PE; Alvarado O; Ravula R; Gout PW; Huang Y
    J Pharmacol Exp Ther; 2010 Mar; 332(3):949-58. PubMed ID: 20007406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased cystine uptake capability associated with malignant progression of Nb2 lymphoma cells.
    Gout PW; Kang YJ; Buckley DJ; Bruchovsky N; Buckley AR
    Leukemia; 1997 Aug; 11(8):1329-37. PubMed ID: 9264389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of cystine uptake by sulfasalazine inhibits proliferation of human mammary carcinoma cells.
    Narang VS; Pauletti GM; Gout PW; Buckley DJ; Buckley AR
    Anticancer Res; 2003; 23(6C):4571-9. PubMed ID: 14981898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sulfasalazine reduces bile acid induced apoptosis in human hepatoma cells and perfused rat livers.
    Rust C; Bauchmuller K; Bernt C; Vennegeerts T; Fickert P; Fuchsbichler A; Beuers U
    Gut; 2006 May; 55(5):719-27. PubMed ID: 16322111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.
    Wahl C; Liptay S; Adler G; Schmid RM
    J Clin Invest; 1998 Mar; 101(5):1163-74. PubMed ID: 9486988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of xc⁻ transporter-mediated cystine uptake by sulfasalazine analogs.
    Shukla K; Thomas AG; Ferraris DV; Hin N; Sattler R; Alt J; Rojas C; Slusher BS; Tsukamoto T
    Bioorg Med Chem Lett; 2011 Oct; 21(20):6184-7. PubMed ID: 21889337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential use of the anti-inflammatory drug, sulfasalazine, for targeted therapy of pancreatic cancer.
    Lo M; Ling V; Low C; Wang YZ; Gout PW
    Curr Oncol; 2010 Jun; 17(3):9-16. PubMed ID: 20567622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of cystine uptake disrupts the growth of primary brain tumors.
    Chung WJ; Lyons SA; Nelson GM; Hamza H; Gladson CL; Gillespie GY; Sontheimer H
    J Neurosci; 2005 Aug; 25(31):7101-10. PubMed ID: 16079392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effects of sulfasalazine and its metabolites on histamine release and TNF-alpha production by mast cells.
    Bissonnette EY; Enciso JA; Befus AD
    J Immunol; 1996 Jan; 156(1):218-23. PubMed ID: 8598465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug repurposing: sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion.
    Sleire L; Skeie BS; Netland IA; Førde HE; Dodoo E; Selheim F; Leiss L; Heggdal JI; Pedersen PH; Wang J; Enger PØ
    Oncogene; 2015 Dec; 34(49):5951-9. PubMed ID: 25798841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells.
    Okamoto K; Saito Y; Ueda H; Narumi K; Furugen A; Kobayashi M
    Biopharm Drug Dispos; 2021 Sep; 42(8):389-392. PubMed ID: 34287957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
    Roh JL; Kim EH; Jang HJ; Park JY; Shin D
    Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism.
    Ma MZ; Chen G; Wang P; Lu WH; Zhu CF; Song M; Yang J; Wen S; Xu RH; Hu Y; Huang P
    Cancer Lett; 2015 Nov; 368(1):88-96. PubMed ID: 26254540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. System X
    Nehser M; Dark J; Schweitzer D; Campbell M; Zwicker J; Hitt DM; Little H; Diaz-Correa A; Holley DC; Patel SA; Thompson CM; Bridges RJ
    Neurochem Res; 2020 Jun; 45(6):1375-1386. PubMed ID: 31754956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The in vitro immunomodulatory effects of sulfasalazine on human polymorphonuclear leukocytes, mononuclear cells, and cultured glomerular mesangial cells.
    Tsai CY; Wu TH; Yu CL; Chou CT
    Life Sci; 2000; 67(10):1149-61. PubMed ID: 10954049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.